Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT01468896 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

NIH

Sponsor class

Conditions

Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Unresectable Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Cetuximab
BIOLOGICAL: Edodekin alfa
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)